XML 43 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727
Combined Statements of Cash Flows - USD ($)
 9 Months Ended 12 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Jun. 30, 2014
Jun. 30, 2013
Cash flows from operating activities        
Net loss $ (5,567,960) $ (3,852,119) $ (5,578,690) $ (2,842,512)
Stock-based compensation expense 749,809 385,342 499,690 316,949
Depreciation and amortization 73,746 63,596 97,476 58,819
Amortization of prepaid research and development - related party (Note 8) 91,488 5,083 35,579  
Deferred taxes (23,910) (549,158) (813,697) (911,305)
(Increase) decrease in prepaid expenses, other 484,053 (324,510) (497,322) (24,000)
(Increase) in prepaid research and development - related party (Note 8) (150,000) (315,000) (465,000)  
Increase in interest payable to Ampio     46,002  
Increase (decrease) in accounts payable (103,157) 582,898 421,870 227,632
Increase (decrease) in related party payable (Note 8) (92,509) 299,469 561,059  
Increase in accrued compensation 98,949      
(Decrease) increase in accrued interest payable (42,673) 12,033    
Increase (decrease) in deferred revenue (64,286) (37,500) 191,071 (50,000)
Net cash used in operating activities (4,546,450) (3,729,866) (5,501,962) (3,224,417)
Cash flows used in investing activities        
Purchase of fixed assets     (9,298) (8,920)
Purchase of patents       (330,000)
Deposits (1,998)      
Net cash used in investing activities (1,998)   (9,298) (338,920)
Cash flows from financing activities        
Contribution from Ampio   637,210 637,210 2,496,747
Proceeds from convertible note from Ampio 3,400,000 4,300,000 4,600,000  
Proceeds from sale of Luoxis common stock (Note 6)       4,652,500
Costs related to sale of Luoxis common stock (Note 6)       (672,210)
Net cash provided by financing activities 3,400,000 4,937,210 5,237,210 6,477,037
Net change in cash and cash equivalents (1,148,448) 1,207,344 (274,050) 2,913,700
Cash and cash equivalents at beginning of period 2,639,650 2,913,700 2,913,700  
Cash and cash equivalents at end of period 1,491,202 4,121,044 2,639,650 2,913,700
Non-cash transactions:        
Issuance of Luoxis stock for patents       50,000
Warrant compensation from Luoxis common stock offering costs (Note 7) $ 313,000     $ 313,064
Issuance of common stock in exchange for Vyrix acquired assets   6,803,356 6,803,356  
Related party research and development liability included in prepaid research and development - related party   $ 300,000 $ 150,000